股本结构
单位：万股
| 公告日期 | 2026-04-30 | 2026-04-30 | 2026-03-26 | 2026-03-26 | 2026-03-26 | 2025-11-21 |
|---|---|---|---|---|---|---|
| 证券总股本 | 13203.26 | 13206.26 | 13203.26 | 13206.26 | 13169.12 | 12126.70 |
| 普通股本 | 13203.26 | 13206.26 | 13203.26 | 13206.26 | 13169.12 | 12126.70 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-04-27 | 2026-04-15 | 2026-03-20 | 2026-03-16 | 2025-12-31 | 2025-11-24 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-04-30 | 13203.26 | 未披露 | 定期报告 | 2026-04-27 |
| 2026-04-30 | 13206.26 | 未披露 | 定期报告 | 2026-04-15 |
| 2026-03-26 | 13203.26 | 未披露 | 定期报告 | 2026-03-20 |
| 2026-03-26 | 13206.26 | 未披露 | 定期报告 | 2026-03-16 |
| 2026-03-26 | 13169.12 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Contingently issuable common stock subject to vesting criteria
Issuance of common stock, stock options exercised
|
2025-12-31 |
| 2025-11-21 | 12126.70 | 未披露 |
更多>>
Common Stock offered 46,091,739 shares by the company
|
2025-11-24 |
| 2025-11-14 | 7517.53 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-11-14 | 7480.79 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock, stock options exercised
|
2025-09-30 |
| 2025-08-14 | 7451.66 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Issuance of common stock, stock options exercised
|
2025-06-30 |
| 2025-05-14 | 7434.15 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Contingently issuable common stock subject to vesting criteria
|
2025-03-31 |
| 2025-03-27 | 7434.15 | 未披露 | 定期报告 | 2025-03-20 |
| 2025-02-24 | 7268.18 | 未披露 |
更多>>
The Company issued 3,319,397 ordinary shares.
|
2025-02-21 |
| 2025-03-27 | 6936.24 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
|
2024-12-31 |
| 2024-10-22 | 6719.26 | 未披露 | 定期报告 | 2024-10-21 |
| 2024-11-18 | 888.26 | 未披露 | 定期报告 | 2024-10-20 |
| 2024-11-14 | 746.41 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock, stock options exercised
|
2024-09-30 |
| 2024-08-14 | 746.41 | 未披露 | 定期报告 | 2024-08-01 |
| 2024-06-27 | 721.61 | 未披露 | 定期报告 | 2024-06-17 |
| 2024-05-22 | 721.61 | 未披露 |
更多>>
Common stock offered 714,527 shares by the company
|
2024-05-22 |
| 2024-05-22 | 650.16 | 未披露 | 定期报告 | 2024-05-20 |
| 2024-05-15 | 647.68 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
|
2024-03-31 |
| 2024-03-27 | 647.68 | 未披露 | 定期报告 | 2024-03-01 |
| 2024-03-27 | 618.63 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
|
2023-12-31 |
| 2023-11-14 | 617.43 | 未披露 | 定期报告 | 2023-11-01 |
| 2023-11-14 | 536.03 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
|
2023-09-30 |
| 2023-08-14 | 534.83 | 未披露 | 定期报告 | 2023-08-01 |
| 2023-08-14 | 529.08 | 未披露 |
更多>>
Inhibikase Therapeutics, Inc. announced that it will effect a 1-for-6 reverse stock split of its common stock.
|
2023-06-30 |
| 2023-06-29 | 3160.00 | 未披露 | 定期报告 | 2023-06-29 |
| 2023-05-15 | 3105.62 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
|
2023-03-31 |
| 2023-03-31 | 2897.72 | 未披露 | 定期报告 | 2023-03-14 |
| 2023-01-27 | 2802.78 | 未披露 |
更多>>
Common Stock offered by the company 2,800,789 shares of common stock.
|
2023-01-27 |
| 2022-05-16 | 2522.71 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock for services
Issuance of common stock, stock options exercised
|
2022-03-31 |
| 2022-03-31 | 2522.71 | 未披露 | 定期报告 | 2022-03-14 |
| 2022-02-07 | 2517.71 | 未披露 | 定期报告 | 2022-02-04 |
| 2021-11-15 | 2515.52 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock, stock options exercised
|
2021-09-30 |
| 2021-08-16 | 2513.33 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock, follow on offering
Issuance of common stock, stock options exercised
|
2021-06-30 |
| 2021-06-18 | 2513.33 | 未披露 |
更多>>
1.Common stock offered 15,000,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on the 10,133,345 shares of common stock outstanding as of June 15, 2021.
|
2021-06-18 |
| 2021-06-11 | 1013.33 | 未披露 | 定期报告 | 2021-06-07 |
| 2021-05-17 | 1005.98 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of common stock
|
2021-03-31 |
| 2021-03-31 | 1005.08 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock
Conversion of notes
Issuance of initial public offering common stock
|
2020-12-31 |
| 2020-12-28 | 1005.08 | 未披露 |
更多>>
1.Common stock offered by the company 1,800,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on the 8,206,706 shares of common stock outstanding as of November 30, 2020
|
2020-12-23 |
From December 31, 2024 to December 31, 2025
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Contingently issuable common stock subject to vesting criteria
Issuance of common stock, stock options exercised
Common Stock offered 46,091,739 shares by the company
From June 30, 2025 to September 30, 2025
Issuance of common stock, stock options exercised
From March 31, 2025 to June 30, 2025
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Issuance of common stock, stock options exercised
From December 31, 2024 to March 31, 2025
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Contingently issuable common stock subject to vesting criteria
The Company issued 3,319,397 ordinary shares.
From December 31, 2023 to December 31, 2024
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
From June 30, 2024 to September 30, 2024
Issuance of common stock, stock options exercised
Common stock offered 714,527 shares by the company
From December 31, 2023 to March 31, 2024
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
From December 31,2022 to December 31,2023
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
From June 30, 2023 to September 30, 2023
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Inhibikase Therapeutics, Inc. announced that it will effect a 1-for-6 reverse stock split of its common stock.
From December 31, 2022 to March 31, 2023
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Common Stock offered by the company 2,800,789 shares of common stock.
From December 31, 2021 to March 31, 2022
Issuance of common stock for services
Issuance of common stock, stock options exercised
From June 30, 2021 to September 30, 2021
Issuance of common stock, stock options exercised
From March 31, 2021 to June 30, 2021
Issuance of common stock, follow on offering
Issuance of common stock, stock options exercised
1.Common stock offered 15,000,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on the 10,133,345 shares of common stock outstanding as of June 15, 2021.
From December 31, 2020 to March 31, 2021
Issuance of common stock
From December 31, 2019 to December 31, 2020
Issuance of common stock
Conversion of notes
Issuance of initial public offering common stock
1.Common stock offered by the company 1,800,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on the 8,206,706 shares of common stock outstanding as of November 30, 2020